Trellis Bioscience Is A Clinical Stage Company Focused On Discovering And Developing Native Human Monoclonal Antibodies To Treat And Prevent Drug Resistantlife Threatening Infectious Diseasesantibodies Are The Immune System S Most Potent Natural Weapon Against Diseasetrellis S Innovative Proprietary Technology Cellspota C Overcomes Technical Obstacles That Have Long Hindered Exploiting The Full Human Antibody Repertoirethis Ideal Source Of Drugs Focuses On The Selection Of Elite Antibodies That Bind Highly Conserved Target Epitopes With High Affinitytrl1068 Is A Native Human Monoclonal Antibodyfor Intravenous Deliverywhose Target Is A Family Of Bacterial Proteinsdnabiithat Play A Critical Role In Maintaining The Structural Integrity Of Biofilms By Anchoring Extracellular Bacterial Dnaednafrom Dead Bacteria Within The Biofilm Matrixtrl1068 Binds At High Affinitykd ~50 Pmto A Highly Conserved Epitope Found In Nearly All Medically Significant Bacteriaincluding Both Gram Positive And Gram Negative Specieshigh Affinity Binding To Dnabii Ensures That The Protein Is Eliminated From The Body And Thus Prevents Its Deposition Elsewhere In The Bodywhere It Could Form Biofilm Metastasesbecause The Bacterial Target Is Only Exposed To The Antibody After The Producing Bacterial Cell Is Deadresistance To This Novel Intervention Is Expected To Be Rarethe Fda Granted Fast Trackqidpqualified Infectious Disease Product And Orphan Drug Designations For Trl1068
